Bayer in India: Intellectual Property Expropriation?

Weiterer Publikationstyp
(Fallstudie)


Details zur Publikation

Autor(en): Bican P, Truong QN
Verlag: ISB-IVEY Publications
Verlagsort: Ontario N6G 0N1, Canada
Jahr der Veröffentlichung: 2014
Seitenbereich: 1-15
Sprache: Englisch


Abstract


Bayer Group needed to reassess its strategies regarding intellectual property, as well as its emphasis on research and development. The Indian government had ruled against Bayer by granting a compulsory licence to a local generic drug manufacturer that allowed them to distribute a copy of Bayer’s blockbuster cancer drug at a fraction of the original price. This ruling demonstrated that pharmaceutical innovation could not be effectively protected by conventional intellectual property rights in emerging markets. As a result, the core of the pharmaceutical industry’s business model was called into question: If ideas and inventions could not be protected, was the there any incentive for firms to innovate? Would this victory for generic drug manufacturers trigger similar rulings elsewhere? Would the prevailing patent-centric IP strategies need to be adapted to emerging markets? Or would innovator companies finally have to withdraw from markets with weak IP protection?


FAU-Autoren / FAU-Herausgeber

Bican, Peter
Lehrstuhl für Technologiemanagement


Autor(en) der externen Einrichtung(en)
Universität St.Gallen


Zitierweisen

APA:
Bican, P., & Truong, Q.N. (2014). Bayer in India: Intellectual Property Expropriation? Ontario N6G 0N1, Canada: ISB-IVEY Publications.

MLA:
Bican, Peter, and Quynh Nhu Truong. Bayer in India: Intellectual Property Expropriation? Ontario N6G 0N1, Canada: ISB-IVEY Publications, 2014.

BibTeX: 

Zuletzt aktualisiert 2018-07-12 um 16:53